Treace Medical Concepts, Inc. (“Treace” or the “Company”)
(NasdaqGS: TMCI), a medical technology company driving a
fundamental shift in the surgical treatment of hallux valgus
(commonly known as bunions), today reported financial results for
the first quarter ended March 31, 2023.
Recent Highlights:
- Revenue of $42.2
million in the first quarter of 2023, a 45% increase over the same
period last year.
- Blended average
revenue per Lapiplasty® procedure kit sold was $6,244, a 13%
increase over the same period last year and a 6% increase
sequentially.
- Gross margin of
80.9% in the first quarter 2023.
- First quarter
revenue contribution from direct sales channel, the industry’s only
direct bunion-focused salesforce, increased to 79% of sales
compared to 63% during the first quarter 2022.
- New interim data1
from ALIGN3D™ clinical study highlighted at the 2023 American
College of Foot and Ankle Surgeons (ACFAS) Annual Scientific
Conference demonstrating 97.3% patient satisfaction rating at 36
months (n=37), with 92% and 90% improvement in walking/standing and
social interaction scores, respectively, through 36 months (n=41);
an 80.8% decrease in pain at 24 months (n=128); and a low
recurrence rate of 0.9% (1 out of 114 patients) observed at 24
months post-surgery2.
- Granted seven
additional U.S. patents year-to-date on innovative systems,
devices, and methods for performing instrumented surgery for
bunions and related deformities. Patent portfolio expands to 47
granted U.S. patents and 51 pending U.S. patent applications.
“First quarter revenue grew 45% with steady
execution of our growth strategies and gains across our key
operating metrics,” said John T. Treace, CEO, Founder and Board
Member of Treace. “With increasing strategic investments into our
direct sales channel, R&D initiatives, and direct-to-consumer
programs, we continue to drive strong revenue growth and expand our
market penetration. These proven commercial programs coupled with
our differentiated technologies well-position us to advance our
mission to improve surgical outcomes for bunion patients.”
First Quarter 2023 Financial Results
Revenue for the first quarter of 2023 was $42.2
million, representing an increase of 45% compared to $29.0 million
in the first quarter of 2022. The increase was driven by an
increased number of Lapiplasty® procedure kits sold as a result of
an expanded surgeon customer base and increased blended average
selling prices due to increased adoption of our newer technologies
and expanding product line.
Gross profit for the first quarter of 2023 was
$34.2 million, representing an increase of 43% compared to a gross
profit of $23.9 million in the first quarter of 2022. Gross margin
totaled 80.9% in the first quarter of 2023, compared to 82.3% in
the first quarter of 2022. The decrease was primarily due to an
increase in payroll costs and an increase in inventory and
obsolescence provisions.
Total operating expenses were $47.9 million in
the first quarter of 2023, including sales and marketing (S&M)
expenses of $33.7 million, research and development (R&D)
expenses of $3.4 million, and general and administrative (G&A)
expenses of $10.9 million. This compared to total operating
expenses of $32.0 million, including S&M expenses of $22.3
million, R&D expenses of $3.1 million, and G&A expenses of
$6.7 million in the first quarter of 2022. Increased operating
expenses in the first quarter of 2023 reflect increased investments
in our commercial initiatives as well as other G&A investments
supporting our growing business.
First quarter net loss attributable to common
stockholders was ($13.5) million, or ($0.23) per share, compared to
a net loss of ($9.0) million, or ($0.16) per share, for the same
period of 2022. Adjusted EBITDA was a loss of ($10.0) million in
the first quarter, compared to a loss of ($6.4) million for the
same period in 2022. See below for additional information and a
reconciliation of non-GAAP financial information.
Financial OutlookTreace is
raising its full year 2023 revenue guidance to $190 million to $196
million, which represents approximately 34% to 38% growth over the
Company’s 2022 revenue. This compares to the prior revenue guidance
of $187 million to $193 million.
_______________1 The ACFAS Scientific Poster,
which includes additional details such as patient demographics,
inclusion/exclusion criteria, and complications reported in the
study, will be accessible on Treace’s website at:
https://www.lapiplasty.com/surgeons/journal-publications/.2 0.9% of
patients (1 out of 114 patients) demonstrated radiographic
recurrence at the 24 month follow up timepoint. 1.4% of patients (2
out of 144 patients) demonstrated radiographic recurrence at the 12
month follow up timepoint.
Webcast and Conference Call
DetailsTreace will host a conference call today, May 8,
2023, at 4:30 p.m. ET to discuss its first quarter 2023 financial
results. Investors interested in listening to the conference call
may do so by registering. Once registered, participants will
receive dial-in numbers and a unique pin to join the call and ask
questions. The live webcast of the conference call will be
available on the Investor Relations section of the Company’s
website at https://investors.treace.com/. The webcast will be
archived on the website following the completion of the call.
Use of Non-GAAP Financial
MeasuresTo supplement the financial results presented in
accordance with GAAP, this earnings release presents Adjusted
EBITDA, which the Company defines as net loss before depreciation
and amortization expense, share-based compensation expense,
interest income, interest expense, and taxes. As of March 31, 2023,
in its calculation of Adjusted EBITDA, the Company is subtracting
interest income from net loss as interest income is more
significant this quarter and is expected to be significant for the
full year 2023. Prior period results for Adjusted EBITDA have been
updated to be consistent with the current quarter’s presentation.
Non-GAAP financial measures such as Adjusted EBITDA are presented
in addition to, and not as a substitute for, or superior to,
financial measures calculated in accordance with GAAP. Management
uses these non-GAAP financial measures to evaluate the Company’s
operating performance and trends, as well as for making planning
decisions. The Company believes that Adjusted EBITDA helps to
identify underlying trends in the Company’s business that may
otherwise be masked by the effect of the income and expenses and
other items that it excludes in its calculation of Adjusted EBITDA.
Accordingly, the Company believes these non-GAAP financial measures
provide useful information to investors and others in understanding
and evaluating the Company’s operating results, enhancing the
overall understanding of its past performance and future prospects,
and allowing for greater transparency with respect to key financial
metrics used by the Company’s management in their financial and
operational decision-making. The Company also presents these
non-GAAP financial measures because it believes investors, analysts
and rating agencies consider them to be a useful metrics in
measuring the Company’s performance against other companies and its
ability to meet its debt service obligations.
There are limitations related to the use of
non-GAAP financial measures such as Adjusted EBITDA because they
are not prepared in accordance with GAAP, may exclude significant
income and expenses required by GAAP to be recognized in the
Company’s financial statements, and may not be comparable to
non-GAAP financial measures used by other companies. The Company
encourages investors to carefully consider its results under GAAP,
as well as its supplemental non‐GAAP information and the
reconciliation between these presentations, to more fully
understand its business. Reconciliations between GAAP and non‐GAAP
results are presented below.
Forward-Looking StatementsThis
press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
All statements other than statements of historical fact are
forward-looking statements, including, but not limited to the
Company’s expectations that it is well positioned to advance its
mission to improve surgical outcomes for bunion patients; and the
Company’s expected revenue and revenue growth rates for full year
2023. Forward-looking statements are based on management’s current
assumptions and expectations of future events and trends, which
affect or may affect the Company’s business, strategy, operations
or financial performance, and actual results and other events may
differ materially from those expressed or implied in such
statements due to numerous risks and uncertainties. Forward-looking
statements are inherently subject to risks and uncertainties, some
of which cannot be predicted or quantified. Factors that could
cause actual results or other events to differ materially from
those contemplated in this press release can be found in the Risk
Factors section of Treace’s public filings with the Securities and
Exchange Commission (SEC), including its Annual Report on Form 10-K
for the year ended December 31, 2022, which was filed with the SEC
on March 8, 2023 and its Quarterly Report on Form 10-Q for the
quarter ended March 31, 2023, expected to be filed with the SEC on
May 9, 2023. Because forward-looking statements are inherently
subject to risks and uncertainties, you should not rely on these
forward-looking statements as predictions of future events. These
forward-looking statements speak only as of their date and, except
to the extent required by law, the Company undertakes no obligation
to update these statements, whether as a result of any new
information, future developments or otherwise. The Company’s
results for the quarter ended March 31, 2023 are not necessarily
indicative of our operating results for any future periods.
About Treace Medical
ConceptsTreace Medical Concepts, Inc. is a medical
technology company with the goal of advancing the standard of care
for the surgical management of bunion and related midfoot
deformities. Bunions are complex 3-dimensional deformities that
originate from an unstable joint in the middle of the foot and
affect approximately 65 million Americans, of which Treace
estimates 1.1 million are annual surgical candidates. Treace has
pioneered and patented the Lapiplasty® 3D Bunion Correction™ System
– a combination of instruments, implants, and surgical methods
designed to surgically correct all 3 planes of the bunion deformity
and secure the unstable joint, addressing the root cause of the
bunion and helping patients get back to their active lifestyles.
Treace expanded its offering with the Adductoplasty® Midfoot
Correction System, designed for reproducible surgical correction of
the midfoot to provide further support to hallux valgus patients.
For more information, please visit www.treace.com.
Contacts:
Treace Medical ConceptsMark L. HairChief
Financial Officermhair@treace.net(904) 373-5940
Investors:
Gilmartin GroupLynn Lewis or Vivian
CervantesIR@treace.net
Treace Medical Concepts, Inc.
Statements of Operations and Comprehensive
Loss(in thousands, except share and per share
amounts)
|
Three Months
EndedMarch 31, |
|
|
2023 |
|
|
2022 |
|
Revenue |
$ |
42,195 |
|
|
$ |
29,047 |
|
Cost of
goods sold |
|
8,039 |
|
|
|
5,130 |
|
Gross
profit |
|
34,156 |
|
|
|
23,917 |
|
Operating expenses |
|
|
|
|
|
Sales and marketing |
|
33,655 |
|
|
|
22,299 |
|
Research and development |
|
3,412 |
|
|
|
3,052 |
|
General and administrative |
|
10,865 |
|
|
|
6,662 |
|
Total
operating expenses |
|
47,932 |
|
|
|
32,013 |
|
Income
(loss) from operations |
|
(13,776 |
) |
|
|
(8,096 |
) |
Interest income |
|
1,479 |
|
|
|
9 |
|
Interest expense |
|
(1,285 |
) |
|
|
(951 |
) |
Other income, net |
|
128 |
|
|
|
2 |
|
Other
non-operating income (expense), net |
|
322 |
|
|
|
(940 |
) |
Net
loss |
$ |
(13,454 |
) |
|
$ |
(9,036 |
) |
|
|
|
|
|
|
Other
comprehensive income (loss): |
|
|
|
|
|
Unrealized loss on marketable securities |
$ |
(29 |
) |
|
$ |
— |
|
Comprehensive income (loss) |
$ |
(13,483 |
) |
|
$ |
(9,036 |
) |
|
|
|
|
|
|
Net loss
per share attributable to common stockholders, basic and
diluted |
$ |
(0.23 |
) |
|
$ |
(0.16 |
) |
Weighted-average shares used in computing net loss per share
attributable to common stockholders, basic and diluted |
|
58,723,760 |
|
|
|
54,827,665 |
|
|
|
|
|
|
|
|
|
Note: A change in presentation has been made
within the Statement of Operations and Comprehensive Loss for the
three months ended March 31, 2022, reclassifying $0.4 million of
surgical instrument expense from cost of goods sold to sales and
marketing expense to conform with the current year’s presentation.
Please refer to supplemental materials related to quarterly 2022
results available on our investor relations website.
Treace Medical Concepts, Inc.
Balance Sheets (in thousands, except share
and per share amounts)
|
|
March 31, |
|
|
December 31, |
|
|
|
2023 |
|
|
2022 |
|
Assets |
|
|
|
|
|
|
Current
assets |
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
29,613 |
|
|
$ |
19,473 |
|
Marketable securities, short-term |
|
|
141,049 |
|
|
|
61,779 |
|
Accounts receivable, net of allowance for doubtful accounts of $677
and $735 as of March 31, 2023 and December 31, 2022,
respectively |
|
|
25,365 |
|
|
|
29,196 |
|
Inventories |
|
|
22,519 |
|
|
|
19,330 |
|
Prepaid expenses and other current assets |
|
|
4,587 |
|
|
|
3,624 |
|
Total
current assets |
|
|
223,133 |
|
|
|
133,402 |
|
Property
and equipment, net |
|
|
15,915 |
|
|
|
15,338 |
|
Operating lease right-of-use assets |
|
|
9,907 |
|
|
|
10,138 |
|
Other
non-current assets |
|
|
215 |
|
|
|
146 |
|
Total
assets |
|
$ |
249,170 |
|
|
$ |
159,024 |
|
Liabilities and Stockholders’ Equity |
|
|
|
|
|
|
Current
liabilities |
|
|
|
|
|
|
Accounts payable |
|
$ |
5,076 |
|
|
$ |
8,668 |
|
Accrued liabilities |
|
|
7,971 |
|
|
|
6,216 |
|
Accrued commissions |
|
|
5,891 |
|
|
|
7,356 |
|
Accrued compensation |
|
|
3,300 |
|
|
|
7,666 |
|
Operating lease and other liabilities |
|
|
1,058 |
|
|
|
339 |
|
Total
current liabilities |
|
|
23,296 |
|
|
|
30,245 |
|
Long-term debt, net of discount of $1,215 and $1,289 as of
March 31, 2023 and December 31, 2022, respectively |
|
|
52,785 |
|
|
|
52,711 |
|
Operating lease liabilities, net of current portion |
|
|
15,447 |
|
|
|
15,539 |
|
Other
long-term liabilities |
|
|
25 |
|
|
|
— |
|
Total
liabilities |
|
|
91,553 |
|
|
|
98,495 |
|
Commitments and contingencies (Note 7) |
|
|
|
|
|
|
Stockholders’ equity |
|
|
|
|
|
|
Preferred stock, $0.001 par value, 5,000,000 shares authorized as
of March 31, 2023 and December 31, 2022; 0 shares issued
and outstanding as of March 31, 2023 and December 31,
2022 |
|
|
— |
|
|
|
— |
|
Common stock, $0.001 par value, 300,000,000 shares authorized;
61,280,703 issued and outstanding as of March 31, 2023;
300,000,000 shares authorized; 55,628,208 issued and outstanding as
of December 31, 2022 |
|
|
61 |
|
|
55 |
|
Additional paid-in capital |
|
|
255,786 |
|
|
|
145,221 |
|
Accumulated deficit |
|
|
(98,174 |
) |
|
|
(84,720 |
) |
Accumulated other comprehensive (loss) income |
|
|
(56 |
) |
|
|
(27 |
) |
Total
stockholders’ equity |
|
|
157,617 |
|
|
|
60,529 |
|
Total liabilities and stockholders’ equity |
|
$ |
249,170 |
|
|
$ |
159,024 |
|
|
|
|
|
|
|
|
|
|
Treace Medical Concepts, Inc.
Statements of Cash Flows (in
thousands)
|
|
Three Months Ended March 31, |
|
|
|
2023 |
|
|
2022 |
|
Cash flows from operating activities |
|
|
|
|
|
|
Net loss |
|
$ |
(13,454 |
) |
|
$ |
(9,036 |
) |
Adjustments to reconcile net loss to net cash used in
operating activities |
|
|
|
|
|
|
Depreciation and amortization expense |
|
|
924 |
|
|
|
334 |
|
Provision for allowance for doubtful accounts |
|
|
38 |
|
|
|
30 |
|
Share-based compensation expense |
|
|
2,692 |
|
|
|
1,409 |
|
Non-cash lease expense |
|
|
626 |
|
|
|
336 |
|
Amortization of debt issuance costs |
|
|
74 |
|
|
|
45 |
|
Recovery of loss reserve for surgical instruments |
|
|
(23 |
) |
|
|
— |
|
Gain on fair value adjustment to derivative liability |
|
|
— |
|
|
|
(90 |
) |
Accretion (amortization) of discount (premium) on marketable
securities, net |
|
|
(297 |
) |
|
|
— |
|
Net
changes in operating assets and liabilities: |
|
|
|
|
|
|
Accounts Receivable |
|
|
3,793 |
|
|
|
2,542 |
|
Inventory |
|
|
(3,189 |
) |
|
|
(551 |
) |
Prepaid expenses and other assets |
|
|
(963 |
) |
|
|
1,233 |
|
Other non-current assets |
|
|
(69 |
) |
|
|
(134 |
) |
Payable to broker for unsettled marketable security purchases |
|
|
710 |
|
|
|
— |
|
Operating lease liabilities |
|
|
(478 |
) |
|
|
(133 |
) |
Accounts payable |
|
|
(3,592 |
) |
|
|
(607 |
) |
Accrued liabilities |
|
|
(4,076 |
) |
|
|
(2,619 |
) |
Other, net |
|
|
25 |
|
|
|
— |
|
Net cash used in operating activities |
|
|
(17,259 |
) |
|
|
(7,241 |
) |
|
|
|
|
|
|
|
Cash flows from investing activities |
|
|
|
|
|
|
Purchases of available-for-sale marketable securities |
|
|
(99,550 |
) |
|
|
— |
|
Maturities of available-for-sale marketable securities |
|
|
20,548 |
|
|
|
— |
|
Purchases of property and equipment |
|
|
(1,478 |
) |
|
|
(1,481 |
) |
Net cash used in investing activities |
|
|
(80,480 |
) |
|
|
(1,481 |
) |
|
|
|
|
|
|
|
Cash flows from financing activities |
|
|
|
|
|
|
Proceeds from issuance of common stock from public offering, net of
issuance costs and underwriting discount of $7.5 million |
|
|
107,527 |
|
|
|
— |
|
Proceeds from exercise of employee stock options |
|
|
352 |
|
|
|
1,372 |
|
Net cash provided by financing activities |
|
|
107,879 |
|
|
|
1,372 |
|
Net increase (decrease) in cash and cash equivalents |
|
|
10,140 |
|
|
|
(7,350 |
) |
Cash and
cash equivalents at beginning of period |
|
|
19,473 |
|
|
|
105,833 |
|
Cash and
cash equivalents at end of period |
|
$ |
29,613 |
|
|
$ |
98,483 |
|
|
|
|
|
|
|
|
Supplemental disclosure of cash flow
information: |
|
|
|
|
|
|
Cash paid for interest |
|
$ |
1,285 |
|
|
$ |
951 |
|
Operating lease right-of-use assets obtained in exchange for new
lease liabilities |
|
$ |
— |
|
|
$ |
15,300 |
|
Operating lease right-of-use asset and lease liability adjustment
due to lease incentive |
|
$ |
(35 |
) |
|
$ |
— |
|
Unrealized losses on marketable securities |
|
$ |
29 |
|
|
$ |
— |
|
|
|
|
|
|
|
|
|
|
Treace Medical Concepts,
Inc.Reconciliation of GAAP Net Loss to EBITDA
& Adjusted EBITDA(in thousands)
|
Three Months
EndedMarch 31, |
|
|
2023 |
|
|
2022 |
|
Net loss |
$ |
(13,454 |
) |
|
$ |
(9,036 |
) |
Adjustments: |
|
|
|
|
|
Interest income |
|
(1,479 |
) |
|
|
(9 |
) |
Interest expense |
|
1,285 |
|
|
|
951 |
|
Taxes |
|
— |
|
|
|
— |
|
Depreciation & Amortization |
|
924 |
|
|
|
334 |
|
EBITDA |
$ |
(12,724 |
) |
|
$ |
(7,760 |
) |
Share-based compensation expense |
|
2,692 |
|
|
|
1,409 |
|
Adjusted EBITDA |
$ |
(10,032 |
) |
|
$ |
(6,351 |
) |
|
|
|
|
|
|
|
|
Treace Medical Concepts (NASDAQ:TMCI)
過去 株価チャート
から 4 2024 まで 5 2024
Treace Medical Concepts (NASDAQ:TMCI)
過去 株価チャート
から 5 2023 まで 5 2024